Discover the advantages of needle-free vaccines and which companies are developing their own promising delivery solutions in ...

The Food and Drug Administration (FDA) recently gave approval for clinical trials in the U.S. of a COVID-19 nasal vaccine ...

When news breaks, you need to understand what matters — and what to do about it. At Vox, our mission to help you make sense of the world has never been more vital. But we can’t do it on our own.

Vaxxas, a clinical-stage biotechnology company, today announced the appointments of three globally respected vaccine experts as advisors to its product development and strategy team as the company ...

Scientists at Stanford are developing a painless, topical vaccine using a common skin bacterium to trigger immunity.

Vaxxas’ proprietary high-density microarray patch (HD-MAP) technology is currently being evaluated in a phase 1 clinical study of the first needle-free COVID-19 vaccine, having demonstrated ...

A needle-free injection is a method of delivering medication into the body without using a needle Read this article to learn ...

Clinical-stage biotechnology company Vaxxas has appointed three global vaccine experts as advisors as it progresses its ...

is awarding $3.7 million in new funding to Micron Biomedical to advance research into an innovative technology that could overcome critical vaccine access challenges with needle-free administration.

Vaxxas has announced that the CEPI, has approved the progression of a $7.2 million program to develop heat-stable, ...

Vaxxas’ proprietary HD-MAP offers the potential for needle-free vaccination, reduction of refrigerated storage, and self-administration, making it less expensive, more effective and easier to ...